Literature DB >> 24576928

[Diagnostic criteria for primary osteoporosis : year 2012 revision].

Satoshi Soen1.   

Abstract

In 1995, the Japanese Society for Bone and Mineral Metabolism (now the Japanese Society for Bone and Mineral Research) established The Osteoporosis Diagnostic Criteria Review Committee. Following discussion held at the 13th scientific meeting of the Society in 1996, the Committee, with the consensus of its members, proposed diagnostic criteria for primary osteoporosis. The Committee revised those criteria in 1996 and again in 2000. Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis aimed at obtaining international consistency and made a revised edition based on the new findings in 2012.

Entities:  

Mesh:

Year:  2014        PMID: 24576928     DOI: CliCa1403323329

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  9 in total

1.  Calcitonin gene-related peptide stimulates proliferation and osteogenic differentiation of osteoporotic rat-derived bone mesenchymal stem cells.

Authors:  Wei Liang; Xianglong Zhuo; Zhongfei Tang; Xiaomou Wei; Bing Li
Journal:  Mol Cell Biochem       Date:  2015-01-07       Impact factor: 3.396

2.  Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics.

Authors:  Kengo Takahashi; Takao Setoguchi; Hiroki Tawaratsumida; Yoshiya Arishima; Hiroyuki Tominaga; Yasuhiro Ishidou; Satoshi Nagano; Sanae Shigemizu; Noriko Aoki; Masaki Akimoto; Hideo Otsubo; Takemasa Matsuda; Hironori Kakoi; Toshihiko Izumi; Shunsuke Nakamura; Masahiro Yokouchi; Nobuhiko Sunahara; Setsuro Komiya
Journal:  BMC Musculoskelet Disord       Date:  2015-09-30       Impact factor: 2.362

3.  Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs.

Authors:  Hiroto Tokumoto; Hiroyuki Tominaga; Yoshiya Arishima; Go Jokoji; Masaki Akimoto; Hideo Ohtsubo; Eiji Taketomi; Nobuhiko Sunahara; Satoshi Nagano; Yasuhiro Ishidou; Setsuro Komiya; Takao Setoguchi
Journal:  Nutrients       Date:  2018-02-18       Impact factor: 5.717

4.  Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.

Authors:  Takako Suzuki; Yukio Nakamura; Hiroyuki Kato
Journal:  Nutrients       Date:  2018-02-27       Impact factor: 5.717

5.  Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis.

Authors:  Takako Suzuki; Yukio Nakamura; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-03-01       Impact factor: 2.423

6.  Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis.

Authors:  Takako Suzuki; Yukio Nakamura; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-12-18       Impact factor: 2.423

7.  Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.

Authors:  Yukio Nakamura; Mikio Kamimura; Shota Ikegami; Keijiro Mukaiyama; Shigeharu Uchiyama; Akira Taguchi; Hiroyuki Kato
Journal:  BMC Endocr Disord       Date:  2015-12-15       Impact factor: 2.763

8.  Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.

Authors:  Yukio Nakamura; Mikio Kamimura; Akio Morikawa; Akira Taguchi; Takako Suzuki; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-03-14       Impact factor: 2.423

9.  Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment.

Authors:  Yukio Nakamura; Takako Suzuki; Mikio Kamimura; Kohei Murakami; Shota Ikegami; Shigeharu Uchiyama; Hiroyuki Kato
Journal:  Bone Res       Date:  2017-10-10       Impact factor: 13.567

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.